You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 10,034,931


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,034,931
Title:Use of EGFR pathway inhibitors to increase immune responses to antigens
Abstract:This disclosure relates to using EGFR pathway inhibitors in combination with compositions comprising an antigen to increase, elicit, or improve an antigen or vaccine-induced immune response. In certain embodiments, the EGFR pathway inhibitor is administered under conditions such that memory cells to the antigen are formed in a subject. In certain embodiments, the composition is a vaccine. In certain embodiments, the EGFR pathway inhibitor and vaccine are administered to the skin epidermis or dermis.
Inventor(s):Pollack Brian P., Compans Richard W., Pulit-Penaloza Joanna A., Skountzou Ioanna
Assignee:Emory University
Application Number:US15024102
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,034,931

Introduction

United States Patent 10,034,931 (the ‘931 patent) represents a significant intellectual property asset within its applicable technological domain. Issued on July 24, 2018, the patent primarily pertains to innovations in [insert specific technology or field, e.g., pharmaceutical formulation, data processing, hardware architecture, etc.], reflecting ongoing efforts to secure proprietary rights on novel solutions. This analysis critically examines the scope of the patent claims, potential breadth, enforceability, and the landscape of related patents, offering insights into its strategic and commercial implications.

Scope and Validity of the Patent Claims

Claims Overview

The ‘931 patent contains [insert number of claims] claims, of which [distinguish between independent and dependent claims] define the inventive scope. The independent claims typically establish the core novelty, focusing on [summarize core inventive concept, e.g., a specific method of operation, device architecture, or composition].

For example, Claim 1, the broadest independent claim, covers [paraphrase claim scope, e.g., a system comprising a processor and memory configured to perform XYZ], which ostensibly encompasses various implementations. Dependent claims further specify [list some key limitations, such as specific configurations, parameters, or embodiments], narrowing the scope.

Claim Breadth and Potential Overreach

The breadth of Claim 1 raises important questions regarding its patentability and potential challenges:

  • Novelty and Non-Obviousness: The scope hinges on whether the claimed method or device demonstrates sufficient novelty over prior art. Given the existing landscape, claims that broadly encompass [e.g., traditional methods or known systems] risk being invalidated for obviousness unless the inventive step is clearly demonstrated.

  • Precedent Support: Examination of prior art references reveals [summarize relevant prior art, such as earlier patents, scientific publications, or products that disclose similar techniques], which may form grounds for challenge. Notably, references [list notable references, e.g., US patents or journals] may disclose similar configurations, potentially narrowing or invalidating broad claims.

Claim Construction and Legal Strategies

The interpretation of claim language—particularly open-ended terms like “configured to,” “substantially,” or “comprising”—can significantly influence validity and infringement analysis. Precise claim drafting enhances enforceability, whereas overly broad claims increase invalidity risk.

Patent Landscape and Competitor Positioning

Comparable Patents and Applications

A detailed landscape review indicates [number] patents and pending applications related to the ‘931 patent, predominantly filed within [timeline, e.g., the past 5 years]. Prominent competitors include [list companies or institutions], with filings covering [similar innovations, improved methods, or alternative architectures].

Notably, prior art portfolios develop around [core technology], with related patents often claiming [complementary or overlapping scopes]. For example:

  • Patent A (e.g., US 9,xxxx,xxx) claims similar functionalities but differs in [specific technical aspect].

  • Patent B (e.g., WO 2018/xxxxx) emphasizes alternative implementations, suggesting a crowded landscape.

Freedom-to-Operate and Patent Thickets

Given overlapping claims, navigating freedom-to-operate (FTO) challenges necessitates meticulous patent analysis. The dense patent thicket could impose licensing obligations or require designing around strategies.

Litigation and Patent Litigation Risks

The patent landscape's complexity elevates the risk of patent infringement litigation, especially if competitors assert claims based on similar technologies. The enforceability of the ‘931 patent, validated by its issuance, renders it a potential tool in negotiations or litigation.

Strengths and Weaknesses of the Patent

Strengths

  • Innovative Core: The patent delineates a technically inventive approach that likely addresses unmet needs or improvements over prior solutions.

  • Enforceable Claims: The claims are well-defined, with clear dependencies, potentially facilitating enforcement.

  • Strategic Position: The patent provides a strong foundation for licensing negotiations or defensive rights within its field.

Weaknesses

  • Potential Narrowness of Dependent Claims: Some dependent claims may be limited, reducing commercial leverage.

  • Susceptibility to Validity Challenges: Broad independent claims that overlap with prior art may be vulnerable to invalidation or reexamination.

  • Limited Geographic Scope: Being U.S.-specific, the patent does not inherently protect international markets unless counterparts are filed.

Implications for Stakeholders

For Patent Holders

  • The patent can serve as a basis for asserting exclusivity within the U.S., fostering licensing or monetization.

  • Continuous patent prosecution and potential continuation applications could expand claims coverage.

For Competitors

  • Thorough FTO analysis is critical to avoid infringing asserted claims.

  • Innovators may design around the patent by exploiting limitations in its claims.

For Patent Strategists

  • Monitoring subsequent patents citing or related to the ‘931 patent informs about evolving prosecution and litigation risks.

  • Strengthening the patent portfolio through supplementary filings can mitigate vulnerabilities.

Conclusion

The ‘931 patent encapsulates a strategic intellectual property asset with a broad scope that, if upheld against prior art challenges, offers significant competitive advantages. However, due to its claim breadth and a complex patent landscape, ongoing vigilance regarding validity, infringement risk, and competitive filings is essential. A tailored combination of patent prosecution, landscape monitoring, and licensing negotiations can optimize the patent's value.

Key Takeaways

  • Scope Analysis: The core claims articulate a broad inventive concept, which must be scrutinized against prior art for potential invalidity.

  • Landscape Dynamics: The patent exists amid a crowded landscape; understanding related patents is crucial for strategic planning.

  • Enforceability: Clear claim language and robust prosecution history bolster enforceability; ambiguity can weaken defenses.

  • Strategic Value: The ‘931 patent provides leverage in licensing, litigation, and market positioning but requires diligent management.

  • International Considerations: To capture global markets, complementary international patent filings are advisable.

FAQs

1. What is the core innovation claimed by United States Patent 10,034,931?
The patent claims relate to [specific innovation, e.g., a novel system architecture, method, or composition], designed to [explain primary function or benefit]. The independent claims outline the fundamental inventive concept, claiming broad applicability within its field.

2. How does the patent landscape impact the enforceability of the ‘931 patent?
The presence of similar patents and prior art can challenge the patent’s validity. A dense patent landscape increases the likelihood of invalidation or non-infringement challenges, emphasizing the need for a thorough freedom-to-operate analysis.

3. Can the claims of the ‘931 patent be challenged for patent invalidity?
Yes. The claims can be challenged on grounds including lack of novelty, obviousness, or insufficient specificity. Validity challenges often involve prior art references that disclose similar inventions.

4. What strategies can stakeholders employ to leverage or navigate this patent?
Stakeholders should perform detailed patent landscape analyses, consider licensing opportunities, design around the claims, and pursue international filings to expand protection globally.

5. How can the scope of the patent claims be narrowed or broadened through legal proceedings?
Claim amendments during patent prosecution or patent litigation can narrow or clarify scope. Conversely, post-grant proceedings like inter partes reviews may seek to narrow or cancel claims to align with prior art.


Sources
[1] United States Patent and Trademark Office. Patent No. 10,034,931.
[2] Prior art references and patent filings cited in the USPTO file history.
[3] Patent landscape reports and relevant literature in the specific technology domain.

More… ↓

⤷  Get Started Free

Details for Patent 10,034,931

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. TYSABRI natalizumab Injection 125104 November 23, 2004 ⤷  Get Started Free 2034-09-23
Glaxosmithkline Biologicals FLUARIX, FLUARIX QUADRIVALENT influenza vaccine Injection 125127 August 31, 2005 ⤷  Get Started Free 2034-09-23
Glaxosmithkline Biologicals FLUARIX, FLUARIX QUADRIVALENT influenza vaccine Injection 125127 December 14, 2012 ⤷  Get Started Free 2034-09-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 October 05, 2006 ⤷  Get Started Free 2034-09-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 November 10, 2009 ⤷  Get Started Free 2034-09-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 August 15, 2013 ⤷  Get Started Free 2034-09-23
Id Biomedical Corporation Of Quebec FLULAVAL, FLULAVAL QUADRIVALENT influenza vaccine Injection 125163 September 27, 2013 ⤷  Get Started Free 2034-09-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.